Covid-19 roundup: J&J partners with Catalent on 1B dose vaccine goal; BioNTech, Pfizer begin mRNA vaccine trial in Germany
Second only to the question of how you make a vaccine work is how you make enough of them to match the immediate global demand any approved product inoculation will face.
BARDA has put millions behind manufacturing Moderna’s candidate. Oxford has a large partner in India. CureVac has its own factories and funding to expand. Sanofi is retrofitting existing facilities. Now J&J has unveiled part of their manufacturing answer, signing a collaboration with Catalent, one of the largest biologics manufacturers in the world.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.